A simple blood test could cut through the fog of patient uncertainty
At Monash University in Melbourne, researchers have found that a protein called GFAP, measurable in a simple blood draw, can reliably confirm concussion in adults between 60 and 84 — a population long caught between the ambiguities of aging and the invisible wounds of head injury. Where memory fails and symptoms blur into the ordinary erosions of time, biology may now offer what human testimony cannot: a clear and objective signal. The discovery, published in JAMA Network Open, does not yet change clinical practice, but it illuminates a path forward for one of medicine's most quietly urgent problems.
- Older adults who suffer concussions often cannot reliably report what happened to them, leaving clinicians to diagnose in the dark with tools built for younger, more cognitively intact patients.
- The symptoms of concussion — fatigue, memory loss, confusion — are so similar to normal aging that even experienced doctors struggle to distinguish injury from the passage of time.
- Elevated levels of the GFAP protein in blood plasma now offer an objective biological marker, cutting through patient uncertainty and clinical guesswork with a straightforward test.
- A missed concussion in an elderly patient is not merely a diagnostic failure — it can trigger a second fall, and that fall may be the one that kills them.
- Researchers and emergency physicians see the test moving into hospitals, clinics, and first-responder kits, though the distance between a published study and standard clinical protocol remains real work yet to be done.
A team at Monash University in Melbourne has identified a protein in blood that reliably signals concussion in older adults — a finding that could transform how head injuries are diagnosed in one of medicine's most vulnerable populations.
The protein, glial fibrillary acidic protein or GFAP, appears in elevated concentrations in the blood plasma of people aged 60 to 84 who have sustained a concussion. Published in JAMA Network Open, the discovery addresses a problem that has long frustrated clinicians: how to confirm a mild traumatic brain injury in patients whose own memories may be compromised by age. The symptoms of concussion — fatigue, memory loss, difficulty concentrating — overlap so completely with normal aging that distinguishing injury from ordinary wear becomes nearly impossible. Patients may not remember falling, may attribute their confusion to something else, or may minimize what happened to avoid burdening their families.
Lead author Gershon Spitz, a senior research fellow at Monash's School of Psychological Sciences, describes the current diagnostic landscape as deeply ambiguous. Doctors have traditionally relied on patient-reported information, a method riddled with gaps — and the cognitive disruptions that follow a head injury only deepen those gaps further.
The GFAP biomarker offers something independent of what a patient remembers or can articulate. A blood test could eventually become standard in emergency departments, urgent care clinics, and even in the field with first responders. For older adults, the stakes are especially high: a missed concussion means no precautions taken, balance more easily lost, and a second fall that may carry far worse consequences. Professor Biswadev Mitra, an emergency physician at Alfred Hospital in Melbourne, sees earlier detection as a direct means of preventing that cascade.
The pathway from published study to clinical practice still requires training, protocols, and institutional will. But for an aging population at high risk of head injury and its complications, the fact that such a pathway is now visible is itself a meaningful step forward.
A team of researchers at Monash University in Melbourne has identified a biological marker in blood that reliably signals concussion in older adults—a breakthrough that could reshape how emergency rooms and clinics diagnose head injuries in one of medicine's most vulnerable populations.
The discovery centers on a protein called glial fibrillary acidic protein, or GFAP, which appears in elevated concentrations in the blood plasma of people aged 60 to 84 who have sustained a concussion. The finding, published in JAMA Network Open and announced by the university on Saturday, addresses a diagnostic puzzle that has long frustrated clinicians: how to confirm a mild traumatic brain injury in patients whose own memories and cognitive abilities may be compromised by age.
Concussion diagnosis in older adults has always been complicated. The symptoms—memory loss, fatigue, difficulty concentrating—overlap so thoroughly with normal aging that distinguishing injury from the ordinary wear of time becomes nearly impossible. Patients themselves may not remember falling, may not recall the moment of impact, or may attribute their confusion to something else entirely. Doctors have traditionally relied on what patients tell them, a method riddled with gaps and distortions. A patient might not realize they hit their head. They might forget the incident by the time they reach the hospital. Or they might minimize what happened, not wanting to burden their family or admit vulnerability.
Gershon Spitz, a senior research fellow at Monash's School of Psychological Sciences and lead author of the study, describes the current diagnostic landscape as deeply ambiguous. "There is a lot of ambiguity in the way the diagnostic process works currently, and doctors often rely on information reported by patients themselves, which comes with all sorts of bias," he said. The cognitive disruptions that can follow a head injury—loss of consciousness, memory gaps—make it even harder for patients to provide the clear narrative a clinician needs.
The GFAP biomarker offers what researchers call an objective and reliable measure, something independent of what a patient remembers or can articulate. A simple blood test could eventually become standard in emergency departments, urgent care clinics, and even in the field with first responders. The test would provide doctors with concrete biological evidence, cutting through the fog of patient uncertainty and clinical guesswork.
For older adults, the stakes are particularly high. Falls are already a leading cause of injury and death in this age group, and a missed or delayed concussion diagnosis can set off a cascade of problems. A patient who doesn't know they've had a head injury won't take precautions. They'll move too quickly, lose their balance more easily, fall again—and this time the consequences may be far worse. Professor Biswadev Mitra, an emergency physician at the Alfred Hospital in Melbourne, sees the practical value clearly: earlier detection in emergency settings could help "mitigate risk of subsequent falls and improve patient outcomes."
The research suggests that a tool once considered out of reach—a definitive biological test for concussion—may soon be within grasp. What remains is the work of moving from published study to clinical practice, of training staff to order the test, of building it into protocols. But the pathway is now visible. For an aging population at high risk of head injury and its complications, that visibility itself is a kind of relief.
Notable Quotes
There is a lot of ambiguity in the way the diagnostic process works currently, and doctors often rely on information reported by patients themselves, which comes with all sorts of bias.— Gershon Spitz, senior research fellow at Monash School of Psychological Sciences
Earlier detection in emergency settings could help mitigate risk of subsequent falls and improve patient outcomes.— Professor Biswadev Mitra, emergency physician at the Alfred Hospital in Melbourne
The Hearth Conversation Another angle on the story
Why does concussion diagnosis fail so badly in older people?
Because the symptoms of a concussion—memory loss, fatigue, poor concentration—look identical to normal aging. A doctor can't tell if someone is confused because they hit their head or because they're seventy-five. And the patient often can't help. They may not remember falling at all.
So the blood test solves that by being objective.
Exactly. GFAP is a protein that spikes in the blood after a head injury. It doesn't care what the patient remembers. It's just there, measurable, undeniable.
What happens if you miss a concussion in an older person?
They go home thinking they're fine. They move normally, maybe too quickly. They fall again. And the second fall, after an undiagnosed head injury, can be catastrophic.
Is this test ready to use in hospitals now?
Not yet. It's published, it's proven in research. But it needs to move into actual emergency departments, into protocols, into the hands of doctors who know to order it. That's the next phase.
Who benefits most from this?
Older adults living alone, or those with early memory problems. Anyone where the traditional method—asking them what happened—is unreliable. Which is a lot of people.